How to limit uninformative trials: Results from a Delphi working group

Luke Gelinas; Nora Hutchinson; Deborah A Zarin; Barbara E Bierer

doi:10.1016/j.medj.2023.03.003

How to limit uninformative trials: Results from a Delphi working group

Med. 2023 Apr 14;4(4):226-232. doi: 10.1016/j.medj.2023.03.003.

Authors

Luke Gelinas¹, Nora Hutchinson², Deborah A Zarin², Barbara E Bierer³

Affiliations

¹ Advarra, Inc, Columbia, MD, USA; Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Cambridge, MA, USA. Electronic address: [email protected].
² Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Cambridge, MA, USA.
³ Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Cambridge, MA, USA; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 37060899
DOI: 10.1016/j.medj.2023.03.003

Abstract

To be justifiable, clinical trials must test novel hypotheses and produce informative results. However, many trials fail on this score. A Delphi process was used to establish consensus on 35 recommendations across five domains related to the role of scientific review in preventing uninformative trials.

Keywords: Delphi; clinical trials; informative; research waste; scientific review.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Consensus
Delphi Technique*